Antihistamines and related antiallergic and antiulcer agents

Foye's Principles of Medicinal Chemistry: Seventh Edition

Volumn , Issue , 2012, Pages 1045-1072

  Nelson, Wendel L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971330311     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (99)

1. Babe KSJ, Serafin WE. Histamine, bradykinin, and their antagonists. In: Hardman JG, Limbird LE, Mollinoff PB, et al., eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th Ed. New York: McGraw-Hill, 1995:581-600.
2. Zhang M-Q, Leurs R, Timmerman H. Histamine H1-receptor antagonists. In: Wolff ME, ed. Burger's Medicinal Chemistry and Drug Discovery, 5th Ed. New York: John Wiley & Sons, 1997:495-559.
3. Cooper DG, Young RC, Durant GJ, et al. Histamine receptors. In: Emmett JC, ed. Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study, and Therapeutic Application of Chemical Compounds, Vol 3: Membranes and Receptors. Oxford, UK: Pergamon Press, 1990:343-421.
4. Watanabe T, Yamatodani A, Maeyama K, et al. Pharmacology of a-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase. Trends Pharmacol Sci 1990;11:363-367.
5. Moya-Garcia AA, Pino-Angeles A, Gil-Redondo R, et al. Structural features of mammalian histidine decarboxylase reveal the basis for specific inhibition. Br J Pharmacol 2009;157:4-13.
6. Schayer RC, Cooper JAD. Metabolism of 14C histamine in man. J Appl Physiol 1956;9:481-483.
7. Marone G, Genovese A, Granata F, et al. Pharmacological modulation of human mast cells and basophils. Clin Exp Allergy 2002;32:1682-1689.
8. Oliver JM, Kepley CL, Ortega E, et al. Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human FceR1 signaling pathway. Immunopharmacology 2000;48:269-281.
9. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007;7:93-104.
10. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008;9:1215-1223.
11. Church MK, Shute JK, Jensen HM. Mast cell-derived mediators. In: Adkinson NF, Yunginer JW, Busse WW, eds. Middleton's allergy: principles and practice, 6th Ed. Philadelphia: Mosby, 2003:189-212.
12. Goetzl EJ. Lipid mediators of hypersensitivity and inflammation. In: Adkinson NF, Yunginer JW, Busse WW, eds. Middleton's allergy: principles and practice, 6th Ed. Philadelphia: Mosby, 2003:213-230.
13. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009;39:1786-1800.
14. Simons FER, Akdis CA. Histamine and H1-antihistamines. In: Adkinson NF, Bochner BS, Busse WW, eds. Middleton's Allergy: Principles and Practice, 7th Ed. Philadelphia: Mosby, 2009:1517-1547.
15. Bakker RA, Timmerman H, Leurs R. Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. In: Simons FER, ed. Histamine and H1-Antihistamines in Allergic Disease, 2nd Ed. New York: Marcel Dekker, Inc., 2002:27-64.
16. Leurs R, Vollinga RC, Timmerman H. The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor. Prog Drug Res 1995;45:107-165.
17. Leurs R, Bakker RA, Timmerman H, et al. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005;4:107-120.
18. Edwards AM, Holgate ST. The chromones: cromolyn sodium and neodocromil sodium. In: Adkinson NF, Bochner BS, Busse WW, et al., eds. Middleton's Allergy: Principles and Practice, 7th Ed. Philadelphia: Mosby, 2009:1591-1601.
19. Cook EB, Stahl JL, Barney NP, et al. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Med Chem Rev 2004;1:333-347.
20. Forneau E, Bovet D. Recherches sur l'action sypmathicolytique d'un nouveau derive du dioxane. Arch Int Pharmacodyn 1933;46:1781-1910.
21. Simons FER. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-2217.
22. Leurs R, Church MK, Taglialatela M. H1-Antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-498.
23. Ariens EJ. Stereoselectivity of bioactive agents: general aspects. In: Ariens EJ, Soudijn W, Timmermans PBM, eds. Stereochemistry and Biological Activity. Oxford, UK: Blackwell Scientific Publications, 1983:11-32.
24. Casy AF, Ganellin CR, Mercer AD, et al. Analogues of triprolidine: structural influences upon antihistamine activity. J Pharm Pharmacol 1992;44:791-795.
25. Ebnöther A, Weber HP. Synthesis and absolute configuration of clemastine and its isomers. Helv Chim Acta 1976;59:2462-2468.
26. Timmerman H, Rekker RF, Harms AF, et al. Effect of alkyl substitution in drugs. XXII. Antihistaminic and anticholinergic activity of a series of thio ether analogs of substituted diphenhydramines. Arzneim-Forsch 1970;20:1258-1259.
27. Simons FER. Antihistamines. In: Adkinson NF, Yunginer JW, Busse WW, eds. Middleton's Allergy: Principles and Practice, 6th Ed. Philadelphia: Mosby, 2003:834-869.
28. Towart R, Sautel M, Moret E, et al. Investigation of the antihistaminic action of dimethindene maleate (Fenistil) and its optical isomers. In: Timmerman H, van der Goot H, eds. Agents Actions Supplements, Vol. 33: New Perspectives in Histamine Research, 1991:403-408.
29. Hanna PE, Ahmed AE. Conformationally restricted analogs of histamine H1 receptor antagonists: trans- and cis-1,5-diphenyl-3-dimethylaminopyrrolidine. J Med Chem 1973;16:963-968.
30. Shafi'ee A, Hite G. The absolute configurations of the pheniramines, methyl phenidates, and pipradrols. J Med Chem 1969;12:266-270.
31. Otsuki I, Ishiko J, Sakai M, et al. Pharmacological activities of doxepin hydrochloride in relation to its geometrical isomers. Oyo Yakuri 1972;6:973-984.
32. Piwinski JJ, Wong JK, Chan TM, et al. Hydroxylated metabolites of loratadine: an example of conformational diastereomers due to atropisomerism. J Org Chem 1990;55:3341-3350.
33. Remy DC, Rittle KE, Hunt CA, et al. (+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine. J Med Chem 1977;20:1681-1684.
34. Hawes EM. N+-Glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Drug Metab Dispos 1998;26:830-837.
35. Golightly LK, Greos LS. Second-generation antihistamines: actions and effi- cacy in the management of allergic disorders. Drugs 2005;65:341-384.
36. Molimard M, Diquet B, Strolin-Benedetti M. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fund Clin Pharmacol 2004;18:399-411.
37. Garteiz DA, Hook RH, Walker BJ, et al. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim-Forsch 1982;32:1185-1190.
38. Soldovieri MV, Miceli F, Taglialatela M. Cardiotoxic effects of antihistamines: from basics to clinics (...and back). Chem Res Toxicol 2008;21:997-1004.
39. Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005;10:149-155.
40. Pearlstein R, Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 2003;46:2017-2022.
41. Zhang MQ, Caldirola P, Timmerman H. Chiral manipulation of drug selectivity: studies on a series of terfenadine-derived dual antagonists of H1-receptors and calcium channels. Agents Actions 1994;41(Spec. Conf. Issue):C140-C142.
42. Miura M, Uno T, Tateishi T, et al. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007;19:223-227.
43. Sakugawa T, Miura M, Hokama N, et al. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 2009;67:535-540.
44. DuBuske LM. Pharmacology of desloratadine: special characteristics. Clin Drug Investigation 2002;22(Suppl 2):1-11.
45. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-466.
46. Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996;51:165-172.
47. Dizdar EA, Sekerel BE, Tuncer A. Desloratadine: a review of pharmacology and clinical efficacy in allergic rhinitis and urticaria. Therapy 2008;5:817-828.
48. Murdoch D, Goa KL, Keam SJ. Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 2003;63:2051-2077.
49. Ramanathan R, Reyderman L, Kulmatycki K, et al. Disposition of loratadine in healthy volunteers. Xenobiotica 2007;37:753-769.
50. Ramanathan R, Reyderman L, Su AD, et al. Disposition of desloratadine in healthy volunteers. Xenobiotica 2007;37:770-787.
51. Keam SJ, Plosker GL. Rupatadine a review of its use in the management of allergic disorders. Drugs 2007;67:457-474.
52. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs 2004;64:523-561.
53. Gillard M, Van Der Perren C, Moguilevsky N, et al. Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194. Mol Pharmacol 2002;61:391-399.
54. Benedetti MS, Plisnier M, Kaise J, et al. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 2001;57:571-582.
55. van Cauwenberge P, De Belder T, Sys L. A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. Expert Opin Pharmacother 2004;5:1807-1813.
56. Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. Clin Pharmacokinet 2001;40:501-507.
57. Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-1347.
58. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-228.
59. Sharif NA, Hellberg MR, Yanni JM. Antihistamines, topical ocular. In: Wolff ME, ed. Burger's Medicinal Chemistry and Drug Discovery, 5th Ed. New York: John Wiley & Sons, Inc., 1997:255-279.
60. Polivka Z, Budesinsky M, Holubek J, et al. 4H-Benzo[4,5-cyclohepta[1,2-b] thiophenes and 9,10-dihydro derivatives. Sulfonium analogs of pizotifen and ketotifen. Chirality of ketotifen. Synthesis of the 2-bromo derivative of ketotifen. Collect Czech Chem Commun 1989;54:2443-2469.
61. Roberts S, McDonald IM. Inhibitors of gastric acid secretion. In: Abraham DJ, ed. Burger's Medicinal Chemistry and Drug Discovery, Vol. 4: Autocoids, Diagnostics, and Drugs from New Biology, 6th Ed. Hoboken, NJ: Wiley- Interscience, 2003:85-127.
62. Ganellin CR. Discovery of cimetidine. In: Roberts SM, Price BJ, eds. Medicinal Chemsitry: The Role of Organic Chemistry in Drug Research. London: Academic Press, 1985:93-118.
63. Price AH, Brogden RN. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988;36:521-539.
64. Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 1987;12:321-366.
65. Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 2005;59:709-715.
66. Vakil N. Review article: new pharmacological agents for the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther 2004;19:1041-1049.
67. Lindberg P, Brandstrom A, Wallmark B, et al. Omeprazole: the first proton pump inhibitor. Med Res Rev 1990;10:1-54.
68. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+,K+)- ATPase by proton pump inhibitors. J Am Chem Soc 2004;126:7800-7811.
69. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,KATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438-22460.
70. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Aliment Pharmacol Ther 2004;20(Suppl 6):11-19.
71. Galmiche JP, des Varannes SB, Ducrotte P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004;19:655-662.
72. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
73. Andersson T. Single-isomer drugs: true therapeutic advances. Clin Pharmacokinet 2004;43:279-285.
74. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753-768.
75. Lind T, Cederberg C, Ekenved G, et al. Effect of omeprazole, a gastric proton pump inhibitor, on pentagastrin stimulated acid secretion in man. Gut 1983;24:270-276.
76. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-867.
77. Andersson T, Weidolf L. Stereoselective disposition of proton pump inhibitors. Clin Drug Invest 2008;28:263-279.
78. Zhou Q, Yan X-F, Pan W-S, et al. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? World J Gastroenterol 2008;14:2617-2619.
79. Jain SC. A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders. J Indian Med Assn 2009;107:111-113.
80. Hunt RH, Armstrong D, Yaghoobi M, et al. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther 2010;31:648-657.
81. Chisholm MA. Pharmacotherapy of duodenal and gastric ulcerations. Am J Pharm Ed 1998;62:196-203.
82. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108:294-307.
83. Kim H-K, Park S-H, Cheung D-Y, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol 2010;25:1618-1625.
84. De Maeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99-112.
85. Frampton JE. Prucalopride. Drugs 2009;69:2463-2476.
86. Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008;68:981-991.
87. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832-840.
88. Won-Kim S, Kachur JF, Gaginella TS. Stereospecific actions of misoprostol on rat colonic electrolyte transport. Prostaglandins 1993;46:221-231.
89. Nagashima R, Yoshida N. Sucralfate, a basic aluminum salt of sucrose sulfate. I. Behaviors in gastroduodenal pH. Arzneim-Forsch 1979;29:1668-1676.
90. Marks IN. Sucralfate: worldwide experience in recurrence therapy. J Clin Gastroenterol 1987;9(Suppl 1):18-22.
91. Chazot PL. Therapeutic potential of histamine H3 receptor antagonists in dementias. Drug News Perspect 2010;23:99-103.
92. Raddatz R, Tao M, Hudkins RL. Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases. Current Topics Med Chem 2010;10:153-169.
93. Jablonowski JA, Carruthers NI, Thurmond RL. The histamine H4 receptor and potential therapeutic uses for H4 ligands. Mini-Revs Med Chem 2004;4:993-1000.
94. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008;7:41-53.
95. Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 2009;157:24-33.
96. Lim HD, van Rijn RM, Ling P, et al. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 2005;314:1310-1321.
97. Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004;309:404-413.
98. Engelhardt H, Smits RA, Leurs R, et al. A new generation of anti-histamines: histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Dev 2009;12:628-643.
99. Smits RA, Leurs R, de Esch IJP. Major advances in the development of histamine H4 receptor ligands. Drug Discov Today 2009;14:745-753.